Stephen M. Sykes, PhD
Office Phone: 215-728-3539
Lab Phone: 215-728-3563
The overall research goals of the lab are to identify and validate molecular pathways that could provide a foundation for designing novel targeted anti-leukemia therapies or enhancing the efficacy of existing chemotherapies. Leukemia cells often hijack molecular pathways that are critical to the regulation of normal HSPCs. Understanding how these pathways are differentially regulated in leukemia versus normal cell development and contribute to chemotherapy resistance provides the most promising strategy for identifying potential therapeutic targets. As such our lab focuses on three inter-disciplinary directions aimed at:
1. Identifying and delineating molecular events that support leukemia.
2. Understanding how these pathways impact both normal and malignant hematopoiesis.
3. Validating the therapeutic potential of newly discovered pathways in pre-clinical models of AML.
Using this approach, our lab is currently focused on defining how redox biology and stress-activated signaling pathways contribute to leukemogenesis and chemotherapy resistance. Specifically, we are interested in:
1. Understanding how the FOXO family of transcription factors support the differentiation blockade and chemotherapy resistance in AML.
2. Determining the role of ER stress signal transduction pathways in healthy and malignant hematopoietic stem and progenitors.
3. Elucidating the role of the oncogenic kinase PKC epsilon in AML.